Sonnet biotherapeutics announces that its proprietary antibody drug conjugate (adc) platform is available for drug discovery partnerships with potential for producing multiple pipeline drug candidates

Building on proven targeting of the f h ab domain, sonnet's adc platform offers flexible payload capacity and controllable drug-antibody ratios (dar)

SONN Ratings Summary

SONN Quant Ranking